Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.
Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, Hector-Greene M, Sun L, Tewari A, George A, Starr M, Nixon AB, Augustine C, Beasley G, Tyler DS, Osada T, Morse MA, Ling L, Lyerly HK, Blobe GC.
Hanks BA, et al.
J Clin Invest. 2013 Sep;123(9):3925-40. doi: 10.1172/JCI65745. Epub 2013 Aug 8.
J Clin Invest. 2013.
PMID: 23925295
Free PMC article.